These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23491460)

  • 21. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 22. Patient and family fact sheet. Current treatments for multiple sclerosis.
    Kernich CA
    Neurologist; 2005 Mar; 11(2):137-8. PubMed ID: 15733335
    [No Abstract]   [Full Text] [Related]  

  • 23. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J; Freedman M
    Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
    [No Abstract]   [Full Text] [Related]  

  • 24. Multiple sclerosis.
    Boggild M; Ford H
    Clin Evid; 2004 Dec; (12):1843-60. PubMed ID: 15865753
    [No Abstract]   [Full Text] [Related]  

  • 25. [Drug therapy of multiple sclerosis].
    Kinnunen E
    Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
    [No Abstract]   [Full Text] [Related]  

  • 26. [Diagnostics and drug therapy of multiple sclerosis].
    Suomen Neurologinen Yhdistys ry
    Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Interferon β].
    Matsushita T
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():196-204. PubMed ID: 26480700
    [No Abstract]   [Full Text] [Related]  

  • 29. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Control of multiple sclerosis relapses with immunomodulating agents.
    Johnson KP
    J Neurol Sci; 2007 May; 256 Suppl 1():S23-8. PubMed ID: 17350652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple sclerosis.
    Ford H; Nicholas R
    Clin Evid; 2005 Dec; (14):1637-51. PubMed ID: 16620466
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 33. [New therapeutic methods in the treatment of multiple sclerosis].
    Nervenarzt; 1996 Nov; 67(11 Suppl Neue Ther):1-12. PubMed ID: 9402424
    [No Abstract]   [Full Text] [Related]  

  • 34. [The effect of tobacco smoking on clinical effectiveness of immunomodulatory treatment in multiple sclerosis patients].
    Jernas Ł; Piorunek T; Tokarz E; Wygladalska-Jernas H; Kozubski W; Michalak S
    Przegl Lek; 2012; 69(10):750-2. PubMed ID: 23421025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant therapy for multiple sclerosis.
    Stuart WH; Vermersch P
    Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long-term prevention of MS: effectiveness alone is not enough].
    Haas J
    Krankenpfl J; 2005; 43(7-10):237. PubMed ID: 16515307
    [No Abstract]   [Full Text] [Related]  

  • 37. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?
    Kingwell E; Tremlett H
    Expert Rev Neurother; 2009 Sep; 9(9):1263-5. PubMed ID: 19769440
    [No Abstract]   [Full Text] [Related]  

  • 39. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C; Prosperini L; Sbardella E; Paolillo A
    Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.
    Cunningham A; Gottberg K; von Koch L; Hillert J
    Acta Neurol Scand; 2010 Mar; 121(3):154-60. PubMed ID: 20055771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.